Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33795671.
- Also identified by DOI 10.1038/s41467-021-22362-2 and PMC identifier 8016852.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
We report the identification of three structurally diverse compounds - compound 4, GC376, and MAC-5576 - as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors.
Medical subject headings
- Coronavirus 3C Proteases
- SARS-CoV-2
- Virus Replication
- COVID-19 Drug Treatment